Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Insight Molecular Diagnostics (IMDX) Total Liabilities (2016 - 2026)

Insight Molecular Diagnostics' Total Liabilities history spans 7 years, with the latest figure at $57.2 million for Q4 2025.

  • On a quarterly basis, Total Liabilities rose 20.83% to $57.2 million in Q4 2025 year-over-year; TTM through Dec 2025 was $57.2 million, a 20.83% increase, with the full-year FY2025 number at $57.2 million, up 20.83% from a year prior.
  • Total Liabilities hit $57.2 million in Q4 2025 for Insight Molecular Diagnostics, up from $53.1 million in the prior quarter.
  • Over the last five years, Total Liabilities for IMDX hit a ceiling of $94.3 million in Q4 2021 and a floor of $22.7 million in Q1 2021.
  • Historically, Total Liabilities has averaged $58.0 million across 5 years, with a median of $53.6 million in 2024.
  • Biggest five-year swings in Total Liabilities: surged 330.1% in 2021 and later tumbled 55.95% in 2023.
  • Tracing IMDX's Total Liabilities over 5 years: stood at $94.3 million in 2021, then crashed by 35.88% to $60.5 million in 2022, then fell by 18.51% to $49.3 million in 2023, then fell by 3.94% to $47.4 million in 2024, then rose by 20.83% to $57.2 million in 2025.
  • Business Quant data shows Total Liabilities for IMDX at $57.2 million in Q4 2025, $53.1 million in Q3 2025, and $49.4 million in Q2 2025.